糖尿作为SGLT2抑制剂依从性标志物及真实世界临床结局
本研究利用Optum Labs真实世界数据(2014-2023)的两个队列,评估尿糖作为SGLT2抑制剂依从性客观替代指标的价值。队列1显示SGLT2抑制剂使用与尿糖阳性(≥2+)风险高18.1倍相关(95%CI 16.4-20.0);队列2中58%患者起始后6个月内出现尿糖,且与全因死亡、心衰住院和肾衰竭风险降低相关,而骨折(阴性对照)无关联。
要点
- 尿糖≥2+可作为SGLT2抑制剂依从性的客观替代指标。
- SGLT2抑制剂使用者出现尿糖与全因死亡、心衰住院及肾衰竭风险降低相关。
- 尿糖与骨折风险无关联,支持其作为依从性标志物的特异性。
核心结论
- 尿糖与SGLT2抑制剂依从性相关,且在使用SGLT2抑制剂的患者中与全因死亡、心衰和肾衰竭风险降低相关。
研究设计与样本
- 利用Optum Labs Data Warehouse真实世界数据(2014-2023)的两个队列:队列1含3987例有SGLT2抑制剂药房索赔且用药前后均有尿检的患者;队列2含45711例起始SGLT2抑制剂后6个月内行尿检的患者。
- 尿糖定义为尿糖2+或以上;队列2平均随访3.3年,结局包括全因死亡、心衰住院和肾衰竭,骨折作为阴性对照结局。
主要发现
- 队列1中,SGLT2抑制剂使用( vs 未使用)与尿糖风险高18.1倍相关(95%CI 16.4-20.0),经糖尿病状态调整。
- 队列2中,26657例(58%)在起始SGLT2抑制剂后6个月内出现尿糖,提示依从。
- 经逆概率治疗加权后,尿糖与全因死亡风险降低相关(HR 0.78;95%CI 0.73-0.83)。
- 尿糖与心衰住院风险降低相关(HR 0.87;95%CI 0.78-0.98),与肾衰竭风险降低相关(HR 0.73;95%CI 0.58-0.91)。
- 尿糖与骨折风险无关联(HR 1.00;95%CI 0.95-1.06)。
关键数值与推荐
- 尿糖定义为尿糖2+或以上。
- 队列1中SGLT2抑制剂使用与尿糖的比值比为18.1(95%CI 16.4-20.0)。
- 队列2中58%患者在起始后6个月内出现尿糖。
- 尿糖与全因死亡HR 0.78(95%CI 0.73-0.83),心衰住院HR 0.87(95%CI 0.78-0.98),肾衰竭HR 0.73(95%CI 0.58-0.91)。
临床怎么用
- 在真实世界实践中,可利用常规尿检中的尿糖(≥2+)作为评估SGLT2抑制剂依从性的简便客观指标。
- 对使用SGLT2抑制剂的患者,出现尿糖可能提示依从性良好,并与较低的全因死亡、心衰住院和肾衰竭风险相关。
局限性
- 本研究为观察性真实世界研究,存在残余混杂可能。
- 尿糖作为依从性替代指标可能受其他因素影响,如血糖水平、肾功能等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Glucosuria is a proxy for adherence to sodium-glucose cotransporter 2 (SGLT2) inhibitors. Patients with glucosuria during SGLT2 inhibitor prescriptions have lower risk of mortality, heart failure, and kidney failure. BACKGROUND: Medication nonadherence contributes to the efficacy-effectiveness gap in real-world practice. Glucosuria, routinely measured on urinalysis, may serve as an objective proxy for assessing medication adherence to sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of medications that reduce the risks of kidney disease, heart failure, and mortality. METHODS: We leveraged 2 cohorts from the Optum Labs Data Warehouse real-world data (2014-2023): cohort 1 included 3987 patients with SGLT2 inhibitor pharmacy claims and a urinalysis performed both before and during active fill periods; cohort 2 included 45,711 patients prescribed SGLT2 inhibitors with urinalysis performed within 6 months after initiation. Glucosuria was defined as urine glucose 2+ or greater. Cohort 2 was followed for a mean of 3.3 years for all-cause mortality, heart failure hospitalization, and kidney failure; fractures were used as a negative control outcome. RESULTS: In cohort 1, SGLT2 inhibitor use (versus no use) was associated with 18.1-fold higher odds of glucosuria (95% confidence interval [CI], 16.4 to 20.0), adjusted for diabetes status. In cohort 2, 26,657 (58%) had glucosuria within 6 months of SGLT2 inhibitor initiation, suggesting adherence. After inverse probability of treatment weighting, glucosuria was associated with lower risks of all-cause mortality (hazard ratio [HR], 0.78; 95% CI, 0.73 to 0.83), heart failure hospitalization (HR, 0.87; 95% CI, 0.78 to 0.98), and kidney failure (HR, 0.73; 95% CI, 0.58 to 0.91) compared with no glucosuria. No association was observed with fractures (HR, 1.00; 95% CI, 0.95 to 1.06). CONCLUSIONS: Glucosuria was associated with SGLT2 inhibitor adherence and, among patients prescribed SGLT2 inhibitors, is associated with reductions in risks of all-cause mortality, heart failure, and kidney failure.
引用
- Li Z, Surapaneni A, Charytan DM, et al. Glucosuria as a Marker of Adherence to Sodium-Glucose Cotransporter 2 Inhibitors and Clinical Outcomes in Real-World Practice. J Am Soc Nephrol. 2026. PMID: 42752535. doi:10.1681/ASN.0000001252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。